MARATTO

preprint · bioRxiv (Cold Spring Harbor Laboratory)

Sickle cell status skews malaria parasite genotype at infection

20251 citationOpen accessUniversity of Douala

Abstract

Abstract Sickle hemoglobin (HbS) confers strong protection against symptomatic malaria caused by Plasmodium falciparum . Recently, several P. falciparum alleles (termed Pfsa+ ) were found to be enriched in HbS carriers with malaria, suggesting that parasites may be evolving to overcome HbS protection. However, it is unclear whether HbS places selective pressure on parasites since it has little to no effect against asymptomatic parasitemia, which accounts for the majority of infections. Here, we consider the effect of sickle cell status on Pfsa genotype in asymptomatic infections among 2,277 children in a high malaria transmission region of Cameroon. Consistent with previous studies, we found no significant difference in asymptomatic infection rate according to HbS status. However, HbS was strongly associated with parasite genotype at both Pfsa loci tested. Strong linkage disequilibrium and evidence for within-infection competition further support selection for Pfsa+ alleles in HbS carriers. Our findings reveal that distinct parasites underlie the equal infection rates of HbS and non-HbS carriers, such that HbS has a protective effect prior to malaria symptoms against Pfsa− parasites and Pfsa+ alleles may contribute to HbS carriers’ lower conversion rate to symptomatic disease. A revised evolutionary model for HbS protection against malarial disease is needed involving both resistance and tolerance and ongoing co-evolution with P. falciparum parasites.

Research topics

  • Malaria Research and Control

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1101/2025.09.09.675015

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.